Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LIVE VIDEO WEBCAST ON WEDNESDAY, AUGUST 20 TH AT 2:20 PM ET LA JOLLA, CA, AUG. 14, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, THAT IT WILL PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH BEING HELD VIRTUALLY AUGUST 19-21, 2025. DETAILS FOR THE PRESENTATION ARE AS FOLLOWS: DATE AND TIME: WEDNESDAY, AUGUST 20, 2025 AT 2:20 PM ET PRESENTER: MARC HERTZ, PHD, PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR REGISTRATION LINK: HERE ABOUT WEBULL FINANCIAL WEBULL FINANCIAL IS A LEADING ONLINE BROKERAGE PLATFORM COMMITTED TO EMPOWERING SELF-DIRECTED INVESTORS WITH INNOVATIVE TOOLS AND CUTTING-EDGE TECHNOLOGY.

GRI BIO TO PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH

GRI BIO CEO, MARC HERTZ, PARTICIPATES IN VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT

LONDON, JULY 31, 2025 (GLOBE NEWSWIRE) -- DIGINEX LIMITED (DIGINEX OR THE COMPANY) (NASDAQ: DGNX), A LEADING PROVIDER OF SUSTAINABILITY REGTECH SOLUTIONS, IS DELIGHTED TO ANNOUNCE THE APPOINTMENTS OF ANDREW HARLING AS CHIEF COMMERCIAL OFFICER AND MATTHEW RUSK AS VICE PRESIDENT OF STRATEGIC RELATIONSHIPS, AMERICAS, EFFECTIVE IMMEDIATELY. THESE KEY ADDITIONS TO THE SENIOR TEAM REINFORCE DIGINEX'S COMMITMENT TO ACCELERATING GROWTH AND ADVANCING INNOVATION IN SUSTAINABILITY WORLDWIDE.

TWO SENIOR EXECUTIVES FROM S&P AND THE GLOBAL REPORTING INITIATIVE (GRI) JOIN THE DIGINEX TEAM

 VIDEO WEBCAST NOW AVAILABLE ON-DEMAND LA JOLLA, CA, JULY 22, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED MARC HERTZ, PHD, PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR OF GRI BIO, PARTICIPATED IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE. AS PART OF THE EVENT, DR. HERTZ DOVE DEEPER INTO HIS DEDICATION TO THE COMPANY, HOW HE GOT TO WHERE HE IS TODAY AND PROVIDED INSIGHT INTO WHY HE IS SO PASSIONATE ABOUT THE COMPANY'S PROGRAMS IN DEVELOPMENT.

GRI BIO PARTICIPATES IN THE VIRTUAL INVESTOR WHAT'S YOUR STORY SUMMER SPOTLIGHT ON-DEMAND CONFERENCE

CURRENTLY AVAILABLE TREATMENTS FOR IPF ARE LIMITED TO ONLY TWO APPROVED DRUGS THAT COME WITH SIGNIFICANT SIDE-EFFECTS, LIMITED PATIENT COMPLIANCE AND NO IMPACT ON SURVIVAL

GRI BIO COMPLETES ENROLLMENT IN PHASE 2A STUDY OF GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) HAS RECOMMENDED TO CONTINUE THE STUDY AS PLANNED AS THERE ARE NO SAFETY CONCERNS DEMONSTRATED IN THE DATA REVIEWED

GRI BIO'S GRI-0621 DEMONSTRATES ENCOURAGING SAFETY RESULTS AT PLANNED INTERIM 6-WEEK ANALYSIS IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

LIVE WEBCAST ON WEDNESDAY, MAY 28 TH AT 4:00 PM ET LA JOLLA, CA, MAY 21, 2025 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICEROF GRI BIO WILL PARTICIPATE IN THEVIRTUAL INVESTOR CLOSING BELL SERIESON WEDNESDAY, MAY 28, 2025 AT 4:00 PM ET. AS PART OF THE EVENT, DR. HERTZ WILL PROVIDE A CORPORATE OVERVIEW AND BUSINESS OUTLOOK.

GRI BIO TO PARTICIPATE IN THE VIRTUAL INVESTOR CLOSING BELL SERIES

LIVE WEBCAST FIRESIDE CHAT WITH MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICER ON WEDNESDAY, MAY 21 ST AT 2:40 PM ET

GRI BIO TO PRESENT AT A.G.P.'S ANNUAL HEALTHCARE COMPANY SHOWCASE

POSITIVE INTERIM 2-WEEK SAFETY AND BIOMARKER RESULTS FROM ITS ONGOING PHASE 2A STUDY EVALUATING GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

GRI BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND CONFIRMS GRI-0621 PHASE 2A IPF TRIAL ON TRACK FOR 6-WEEK INTERIM DATA IN Q2 2025 AND TOPLINE DATA IN Q3 2025

THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) HAS RECOMMENDED TO CONTINUE THE STUDY AS PLANNED AS THERE ARE NO SAFETY CONCERNS SEEN IN THE DATA REVIEWED

GRI BIO'S INTERIM BIOMARKER DATA DEMONSTRATE POSITIVE TREND TOWARDS ANTI-FIBROTIC EFFECT OF GRI-0621 IN FIRST TWELVE PATIENTS OF ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

GRI Bio, Inc.

GRI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GRI Bio, Inc.

GRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GRI